My work focuses on a suite of novel mass-spectrometry techniques, collectively known as N-terminomics, that includes using terminal amine isotope labeling of substrates (TAILS). TAILS utilizes isotopic and isobaric labeling to enrich the N-termini of proteolytic products and provides expanded degradomic information and increased proteomic coverage. Using this technical strategy, I have identified substrates for proteases involved in both congenital human diseases including the ciliopathies nephronophthisis and Joubert syndrome (ADAMTS1/5/9 substrates), Marfan syndrome and related connective tissue diseases (ADAMTS6 substrates), and aging-related diseases such aortic aneurysm and osteoarthritis (mast cell chymase/CMA1 substrates). I have also applied N-terminomics to define the landscape of proteolytic remodeling in human thoracic aortic aneurysms, infective endocarditis, a mouse model of heart failure, and other biological/disease contexts using human tissue, mouse models, and cell culture.